Early immune reaction after reduced-intensity cord-blood transplantation for adult patients.
BACKGROUND
To investigate immune reactions after reduced-intensity cord-blood transplantation (RI-CBT).


METHODS
We reviewed medical records of 57 adult RI-CBT recipients. Preparative regimen comprised fludarabine, total-body irradiation, and either melphalan (n=51) or busulfan (n=6). Graft-versus-host disease (GvHD) prophylaxis was cyclosporine. PostRI-CBT immune reactions were classified according to time course: pre-engraftment immune reactions (PIR), engraftment syndrome (ES), and GvHD.


RESULTS
Forty-five patients achieved engraftment at a median of day 19. PIR was characterized by high-grade fever and weight gain and developed on a median of day 9 in 35 of the 45 evaluable patients, including 3 who did not achieve engraftment. PIR subsided spontaneously in 12 patients, whereas corticosteroids were required in the other 23. ES and grade I to IV acute GvHD developed in 36 and 29 patients, respectively. GvHD could not be distinguished from preceding PIR or ES in 10 patients. Causes of the 32 nonrelapse mortalities included GvHD (n=5) and PIR (n=1). There were no significant differences in relapse and nonrelapse deaths between patients with PIR and those without it (18% vs. 5%, and 60% vs. 65%, respectively).


CONCLUSIONS
Immune reactions after RI-CBT can be categorized into three distinct subtypes.
Hematopoietic Stem-cell Transplantation Unit, the National Cancer Center Hospital, Tokyo, Japan.
Yukiko
Y
Kishi
Masahiro
M
Kami
Shigesaburo
S
Miyakoshi
Yoshinobu
Y
Kanda
Naoko
N
Murashige
Takanori
T
Teshima
Eiji
E
Kusumi
Shigeo
S
Hara
Tomoko
T
Matsumura
Koichiro
K
Yuji
Kazuhiro
K
Masuoka
Atsushi
A
Wake
Shinichi
S
Morinaga
Mineo
M
Kanemaru
Tatsuyuki
T
Hayashi
Yuji
Y
Tanaka
Shuichi
S
Taniguchi
D000328:Adult; D000368:Aged; D036101:Cord Blood Stem Cell Transplantation / Q000379:methods*; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control*; D006086:Graft vs Host Disease / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007938:Leukemia / Q000628:therapy; D008223:Lymphoma / Q000628:therapy; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D019172:Transplantation Conditioning / Q000379:methods; D014184:Transplantation, Homologous / Q000276:immunology; D014916:Whole-Body Irradiation
D007166:Immunosuppressive Agents